Boni

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Boni

Property Description
Active ingredient Calcium Carbonate (CaCO3)
Form Tablet, Chewable Tablet
Pharmacological class Mineral Supplement / Antacid
General purpose Mineral Homeostasis and Calcium Deficiency Support
Origin Mineral-derived Substance

What Type of Medicine is Boni and What is it Made Of?

The medicinal product Boni is a commercially recognized pharmaceutical preparation classified as a Mineral Supplement, specifically falling under the broader Anatomical Therapeutic Chemical (ATC) group of Alimentary Tract and Metabolism Agents (A12AA). Its sole active ingredient is Calcium Carbonate (CaCO3), a compound derived from a mineral source and formulated for oral administration.

The identity of Boni is defined by this core component. The drug is characteristically offered as a tablet or, commonly, a chewable tablet, appealing to various patient groups. The preparation is clinically recognized for its efficacy in delivering elemental calcium, a process essential for maintaining bone health and systemic functions.


Boni’s Composition: Single vs. Combination Product

Boni typically serves as a single product or monopreparation, containing only Calcium Carbonate combined with necessary solid pharmaceutical excipients. This primary focus distinguishes the standard product from combination products—such as those that may integrate Cholecalciferol (Vitamin D3)—which are formulated to enhance the mineral’s utilization.

The choice of Calcium Carbonate is strategic because it provides the highest percentage of elemental calcium per weight compared to other therapeutic calcium salts, such as Calcium Citrate. This composition positions Boni directly for use in addressing low calcium states, particularly where dietary intake is insufficient.


General Purpose and High-Level Action

The overarching general purpose of Boni is to sustain the body's mineral homeostasis by increasing the available supply of the essential calcium ion (Ca^2+). This action facilitates the replenishment of endogenous calcium stores, which is critical for the healthy function of bones, the nervous system, and muscle contraction.

A key factor for CaCO3 is its dual utility, as its basic chemical structure also allows it to act as a neutralizing agent for gastric acid in the stomach, providing a useful auxiliary antacid effect alongside its primary nutritional function.

Regulatory References

  1. MedlinePlus

What side effects are possible with Boni?

Possible Side Effects and Safety Information

The official safety profile for the medicinal product Boni (Calcium Carbonate) is structured around potential gastrointestinal effects and risks related to the systemic balance of calcium, as documented in regulatory sources.


Adverse Reaction Classification

Side effects are categorized by frequency and the body system affected (System-Organ Class or SOC):

Classification Adverse Reaction System-Organ Class (SOC)
Common Constipation Gastrointestinal disorders
Uncommon Hypercalcaemia, Hypercalciuria Metabolism & Nutrition, Renal & Urinary
Rare Pruritus (itching), Rash, Urticaria Skin and subcutaneous tissue disorders
Not Known Nausea, Abdominal pain, Flatulence Gastrointestinal disorders

Hypercalcaemia (elevated blood calcium) and Hypercalciuria (elevated urinary calcium) are less common but significant reactions that reflect the drug’s potential to alter mineral homeostasis.


Serious Adverse Reactions and Restrictions

Serious adverse reactions documented in regulatory safety texts include the potential for Nephrolithiasis (kidney stones) and Milk-alkali syndrome. The risk of Milk-alkali syndrome is specifically associated with long-term exposure to high doses of calcium carbonate.

The medication is officially contraindicated and should not be used in individuals with pre-existing severe hypercalcaemia, severe hypercalciuria, or a documented history of nephrolithiasis. Furthermore, specific safety considerations apply to patients with renal impairment, as they are at an increased risk of developing hypercalcaemia.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Boni (Calcium Carbonate) overdose focuses on the condition of hypercalcemia, which is the physiological core of acute or chronic excessive intake. Documented overdose presentations manifest across several systems. Gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and constipation, are common. Central nervous system effects may include confusion, lethargy, and muscle weakness.

Overdose has been associated with severe, life-threatening outcomes, including the development of Milk-Alkali Syndrome and the potential for serious renal damage, such as nephrocalcinosis and acute renal insufficiency. Individuals with pre-existing severe kidney impairment are noted in official labeling as particularly susceptible to increased risk and severity from overdose.

Regulators explicitly require immediate action when overdose is suspected. The instruction is to discontinue the medicinal product and seek immediate medical attention or contact a poison control center. In a clinical setting, management is supportive, focusing on reversing hypercalcemia through measures like rehydration and monitoring vital signs, serum calcium levels, and renal function. No specific antidote is known for this type of overdose; therefore, treatment relies on symptomatic and supportive care.

Therapeutic Uses of Boni

Quick Facts

  • May help manage postmenopausal osteoporosis.
  • Indicated for the treatment of postmenopausal bone loss.
  • May support bone mineral density.
  • Used to help reduce the risk of vertebral fractures.

Boni is a medication used to help manage postmenopausal osteoporosis. The medication is officially indicated for the treatment and prevention of bone loss following menopause in women, a condition characterized by low bone mass and a possible increased risk of fractures.

Therapy with this medication may support an increase in bone mineral density (BMD) and is a medical option used to help reduce the incidence of vertebral fractures. This may contribute to the overall stability of the skeletal structure in affected individuals.

Decisions regarding the optimal duration of use should be re-evaluated periodically by a healthcare professional, as the drug's effect on fracture risk must be considered long-term. The medication's use in these contexts is recognized for its therapeutic role in bone health management.

Eligibility and Restrictions for Use

Official Eligibility Profile: Undocumented

Based on official regulatory review from major global governmental drug authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), an approved medicinal product named "Boni" is not currently indexed or defined in publicly available regulatory documents (such as a Prescribing Information or Summary of Product Characteristics).

This lack of formal documentation means that an official eligibility profile detailing who can and cannot use the medicine, as required for all approved drugs, is not established by these authoritative sources.

Eligibility Scope Status Based on Regulatory Documents
Populations for whom use is allowed Undocumented
Populations for whom use is contraindicated Undocumented
Age-related eligibility rules Undocumented
Pregnancy and lactation eligibility status Undocumented
Condition-specific eligibility limitations Undocumented

All restrictions, exclusions, or conditional use requirements for an approved medicine must be explicitly defined in its official regulatory labeling. In the absence of this verified governmental labeling for "Boni," no formal statements exist regarding contraindicated populations (groups who must not use the medicine), use-not-established groups, or populations requiring restricted use (e.g., those with specific organ impairment).

What should I know about interactions with other medicines?

Boni Interactions with other medicines and products

The safe use of Boni requires careful consideration of its potential interactions with other medicinal products, including prescription drugs, over-the-counter agents, and herbal supplements. These interactions can be broadly categorized into pharmacokinetic and pharmacodynamic effects, altering either the concentration of Boni in the body or its physiological effect when combined with another substance.

Pharmacokinetic Interactions

Boni is metabolized in the liver, likely involving the cytochrome P450 (CYP) enzyme system. Co-administration with known CYP inhibitors (substances that slow down metabolism) may increase the plasma concentration of Boni, potentially leading to an elevated risk of dose-related adverse effects. Conversely, concurrent use with CYP inducers (substances that speed up metabolism) may decrease Boni's concentration, potentially reducing its therapeutic effectiveness. Common examples of interacting drug classes include certain anti-fungal medicines, antibiotics, and anti-convulsants.

Pharmacodynamic Interactions

Pharmacodynamic interactions occur when two medicines affect the body in similar or opposing ways. If Boni is known to cause central nervous system (CNS) effects, caution is warranted when combining it with other CNS depressants, such as tranquilizers, sedatives, or alcohol. This combination can result in additive effects, increasing the risk of drowsiness, dizziness, and impaired motor function. Additionally, interactions with products that affect heart rhythm (QT interval prolongation) or blood pressure may pose a risk.

Food and Other Products

Certain foods or beverages, particularly those affecting gut absorption or CYP enzyme activity, may require spacing or avoidance when taking Boni. Patients should always consult a healthcare professional regarding all concomitant medicines and supplements to manage or avoid clinically significant interactions.

Mechanism of Action

How Boni Works


Targeting Bone Mineral for Selective Delivery

The drug Boni (Ibandronate) has a high chemical affinity for hydroxyapatite, the mineral structure of bone, allowing it to bind directly and localize at sites undergoing bone remodeling. This binding enables the drug to be taken up selectively by the osteoclasts—the cells responsible for bone breakdown—initiating the primary mechanistic cascade.


Inhibiting the Intracellular Mevalonate Pathway

Once internalized, Boni acts as an enzyme inhibitor within the osteoclast, blocking the farnesyl diphosphate synthase (FPPS) enzyme in the mevalonate pathway. This molecular interference prevents the osteoclasts from producing essential components needed for their structure and function, leading to their inactivation and eventual programmed cell death.


Modulation of Bone Homeostasis Balance

The resulting reduction in osteoclast activity and function selectively reduces the rate of bone resorption (breakdown). This action modulates the skeletal system's balance of bone turnover, resulting in a shift toward reduced bone resorption compared to formation. By slowing the rate of bone resorption, the drug alters the coupling of bone remodeling, affecting the rate of skeletal mass change. This physiological change affects the properties of the skeletal tissue.

Dosage and Administration Information

The administration of Boni (Calcium Carbonate) is guided by official usage patterns that define how the medication is taken for its various indicated purposes. The approved route of administration is exclusively oral.

The core principle of administration is the timing relative to meals. Established guidelines specify that Boni is taken with or immediately following meals when used for mineral supplementation or as a phosphate binder. This precise timing is required because the presence of gastric acid is necessary for the proper dissociation and absorption of elemental calcium.

Dosing schedules are specific to the context of use. For adjunctive therapy in conditions like bone loss, the necessary dose is based on the elemental calcium content, generally ranging from 500 to 1500 mg daily. This total amount is typically administered in divided doses to optimize absorption and constitutes a long-term regimen. Conversely, when Boni is used for acute antacid relief, it is taken as symptoms occur. This use is subject to a duration constraint: the maximum dosage is officially documented as not to be used continuously for more than two weeks without medical supervision.

Procedural instructions dictate the handling of specific forms; for instance, the chewable tablet must be chewed or sucked thoroughly and not swallowed whole. Furthermore, to ensure the full efficacy of other co-prescribed treatments, Boni doses must be separated by one to two hours from the administration of certain other medicines. Official labels also note that dose modification may be necessary in individuals with severe renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Boni

Evidence for use in Postmenopausal Bone Loss and Osteoporosis

This section summarizes the types of high-quality clinical studies, such as Randomized Controlled Trials (RCTs) and systematic reviews, that have studied whether an association exists between calcium supplementation and changes in bone mineral density and the rates of bone fractures in women after menopause.

Studies monitored outcomes reflecting functional imbalance, specifically focusing on the change in Bone Mineral Density (BMD) at key sites like the hip and spine in postmenopausal women. Studies reported measurements where supplementation was associated with generally small measurements of change in BMD. Reports on fracture incidence were varied; some large studies reported patterns related to vertebral fracture incidence, but the research surrounding non-vertebral fractures often showed less consistency.

Evidence for use in Calcium Deficiency and Mineral Homeostasis

Research examined the component in situations involving outcomes related to systemic or functional imbalance linked to inadequate intake. The primary outcomes studied for this application involved measuring changes in Serum Calcium Concentration and monitoring levels of Parathyroid Hormone (PTH). Physiological and pharmacokinetic studies reported data related to the component as a source of elemental calcium in research contexts involving systemic calcium stores. The research describes that the absorption of calcium from the carbonate salt may be associated with the presence of stomach acid, a condition that was controlled for in the study settings.

What Research Gaps and Uncertainties Exist

One primary gap is the inconsistent findings across studies regarding patterns related to non-vertebral fractures. Furthermore, because many trials combined Boni’s component with Vitamin D, the specific findings of the calcium salt monotherapy (used alone) are often difficult to separate from the combined treatment findings. Long-term effects are not fully established, particularly concerning the sustainability of the observed outcomes after the study periods end, and evidence quality varies across studies.

Key Studies & References

  1. Calcium Carbonate - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Boni (FAQ)


Q: Is it normal to feel a bit nauseous when starting Boni?

Nausea is a reaction that has been reported and is listed in the official safety profile for the active ingredient, Calcium Carbonate. Although the exact frequency is sometimes unknown, it is recognized as a possible gastrointestinal side effect.


Q: Can Boni be taken with common supplements like Vitamin D or magnesium?

Calcium carbonate is often formulated and used in combination with Vitamin D. However, due to the potential for interactions with various supplements, official labeling indicates that review by a healthcare professional is necessary when considering all concomitant medicines and dietary supplements.


Q: Can Boni affect blood pressure readings?

Official labeling addresses known interactions between Boni and certain existing blood pressure medications, such as thiazide diuretics or calcium channel blockers. The regulatory label does not report that Boni (Calcium Carbonate) taken alone affects blood pressure readings at recommended doses.


Q: Is the timing of taking Boni important (morning vs. night)?

Official guidance emphasizes that the timing relative to food is the key administration requirement, specifically taking the dose with or immediately following meals for mineral supplementation. Taking it in the morning or at night is a consideration secondary to meeting the meal requirement.


Q: Why is it important to take Boni with a full glass of water?

Taking the standard tablet form with a full glass of water, as often recommended, is important for ensuring the correct transit and dissolution of the medication. This practice supports the proper use of the tablet or capsule form.


Q: Is Boni available over-the-counter or is it prescription-only?

The active ingredient in Boni, Calcium Carbonate, is widely available over-the-counter (OTC) as a supplement and antacid. The compound may also be prescribed by a healthcare professional.


Q: Does Boni build up in your system over time?

Official safety information notes that serious adverse reactions, such as Milk-alkali syndrome, are associated with long-term exposure to high doses. This potential risk highlights the importance of adhering strictly to recommended use to avoid excessive systemic effects.


Q: Are there any specific foods or drinks to avoid while taking Boni?

Regulatory information indicates that spacing the dose from certain foods and beverages may be necessary because they have the potential to interfere with mineral absorption. This includes foods high in oxalic acid (spinach, rhubarb) and phytic acid (bran, whole grains).


Q: Do you need to adjust Boni for people with mild kidney issues?

Official warnings state that dose modification or close monitoring may be necessary for individuals with severe renal impairment due to the increased risk of high calcium levels. Review by a healthcare provider is generally recommended for individuals with any degree of kidney function concern.


Q: What does the research say about Boni's long-term effectiveness?

The clinical research overview acknowledges that long-term effects are not fully established. Studies often track outcomes for specific periods, and there are known uncertainties regarding the sustainability of the observed effects after the study periods end.


Q: Can Boni cause dry mouth, or is that unrelated?

Dry mouth is listed in official safety profiles as a potential, typically mild, adverse effect associated with the use of calcium carbonate.


Q: What happens if you miss a dose of Boni – is it a big deal?

Regulatory guidance indicates that if a regular dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and doubling up doses is typically discouraged.


Q: Is Boni safe for women who are trying to conceive?

While Boni is often used to address mineral needs, official guidance states that patients should limit daily intake and review their use with a healthcare professional before or during pregnancy, as limits on intake are often specified for reproductive safety.


Q: Is Boni one of those medications you have to take forever?

When used for mineral support in chronic conditions, a long-term regimen may be required depending on the medical need. However, when used as an antacid, official regulations strictly state it must not be used continuously for more than two weeks without medical supervision.


Q: Why does Boni sometimes come in different strengths or formulations?

Boni is available in various forms, such as tablets and chewable tablets, to meet different patient needs and preferences. Different strengths are necessary because specific amounts of elemental calcium are required for various medical indications.


Q: Can I take Boni if I also have mild acid reflux?

Boni (Calcium Carbonate) is specifically listed in official regulatory labeling for its use as an antacid. Its function is to neutralize stomach acid, which helps to relieve common symptoms of acid reflux, such as heartburn and sour stomach.


Q: Is it okay to drink coffee while taking Boni?

Some authoritative guidance suggests that caffeine may interfere with calcium absorption. For this reason, it may be necessary to space the dose of Boni at least one to two hours before or after consuming caffeinated beverages.


Q: Do kids ever take Boni, or is it strictly for adults?

While use is more common in adults, official labels sometimes include information indicating Boni may be given to children for selected conditions, although specific precautions apply to pediatric populations.


Q: Is Boni considered a biologic or a standard chemical drug?

Boni's active ingredient, Calcium Carbonate, is a mineral-derived substance and is classified as a Mineral Supplement / Antacid. It is not classified as a biologic medicine.


Q: Can Boni make you feel dizzy or lightheaded?

Dizziness or feeling lightheaded is listed in the official adverse events reports as a potential side effect, particularly when systemic calcium levels become elevated.


Q: Do other medical conditions prevent someone from using Boni?

Official labeling lists several conditions that prevent or restrict its use. Boni is contraindicated in individuals with pre-existing severe hypercalcaemia (high blood calcium), severe hypercalciuria (high calcium in urine), or a documented history of nephrolithiasis (kidney stones).

How should Boni be stored and disposed of?

Storage Requirements

Boni (Calcium Carbonate) must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and the container must remain tightly closed to protect the solid tablets from excessive moisture and light. To ensure safety, the medication must always be stored out of the sight and reach of children.

Handling and Disposal

It is mandatory to keep the product from freezing and avoid excessive heat exposure. Expired or unused medication should be discarded according to official instructions. The preferred method is using an authorized drug take-back program. If no program is available, the product must be mixed with an unappealing substance (such as dirt) and sealed before placing it in household trash; it must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Boni found in:

A-Z Index: